To test if EZH2 inhibition enhanced the effect of olaparib in primary BRCA-deficient tumor cells, we treated Lin−CD34+ cells from patients with BRCA-deficient AML and from healthy donors with olaparib with or without UNC1999. This evidence concerns the gene EZH2 and neoplasm.